Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib

BACKGROUND: Despite effective activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib, all non-small cell lung cancer (NSCLC) patients eventually acquire resistance to these agents. Studies have demonstrated that down-regulation of miRNA-145 leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Amri, Jamal, Molaee, Neda, Baazm, Maryam, Karami, Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976848/
https://www.ncbi.nlm.nih.gov/pubmed/31554377
http://dx.doi.org/10.31557/APJCP.2019.20.9.2781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976848/
https://www.ncbi.nlm.nih.gov/pubmed/31554377
http://dx.doi.org/10.31557/APJCP.2019.20.9.2781

Ejemplares similares